|
Mustang Bio inc (NASDAQ: MBIO) |
|
Mustang Bio inc
MBIO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Mustang Bio Inc 's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.76 %
Mustang Bio Inc net loss decreased from $-14 millions, to $-10 millions in III. Quarter 2023,
• More on MBIO's Growth
|
|
Mustang Bio Inc realized a net loss in trailing twelve months.
Mustang Bio Inc realized cash reduction of $ -14.28 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on MBIO's Valuation
|
|
|
|
|
Mustang Bio Inc realized net loss in trailing twelve months.
Mustang Bio Inc realized cash outflow of $ -14.28per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
Mustang Bio Inc Price to Book Ratio is at 5.91 lower than Industry Avg. of 82.31. and higher than S&P 500 Avg. of 0.02
• More on MBIO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com